Merck announced that the FDA has accepted its New Drug Application for Saflutan (tafluprost ophthalmic solution) for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.

Saflutan is a prostaglandin analogue believed to exert its effect by helping to increase the fluid drainage that occurs through the root of the iris in the eye.

For more information call (800) 444-2080 or visit